Drug Profile
Research programme: gene silencing cancer therapeutics - ValiRx
Alternative Names: VAL-101Latest Information Update: 28 Oct 2021
Price :
$50
*
At a glance
- Originator ValiRx plc
- Developer ValiRx
- Class DNA-binding proteins
- Mechanism of Action Genetic transcription inhibitors; Proto-oncogene protein c-bcl-2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pancreatic cancer